Showing 321-330 of 9340 results for "".
Expanding the Field: A New Botulinum Neurotoxin A Enters The US Arena
https://practicaldermatology.com/topics/general-topics/PD0609_07-php/22816/A cosmetic dermatologist with experience using Dysport describes how clinicians may approach the new agent in practice.Is Bone Mineral Density Testing Indicated with Long-Term IM Triamcinolone Acetonide Therapy?
https://practicaldermatology.com/topics/general-topics/PD1208_05-php/22603/Prospective data are lacking, but early findings suggest little if any risk of density-loss among patients on long-term therapy.Malassezia Sensitization in Head and Neck Atopic Dermatitis: A Meta-Analysis of Prevalence and Diagnostic Markers
https://practicaldermatology.com/topics/atopic-dermatitis/malassezia-sensitization-in-head-and-neck-atopic-dermatitis-a-meta-analysis-of-prevalence-and-diagnostic-markers/57253/In the 2024 study by See Tow and Yew entitled, “Malassezia specific IgE in head and neck dermatitis of eczema: A systematic review & meta-analysis,” the authors found no statistically significant differences in prevalence of dominant Malassezia species but concluded that Malassezia-specific IgEPrecision Medicine for AD
https://practicaldermatology.com/columns/atopic-dermatitis-essentials/precision-medicine-for-ad/54826/A Q & A with Derek MaetzoldThe Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,Mergers and Acquisitions in Derm and Aesthetics: Market Outlook
https://practicaldermatology.com/issues/september-2025/mergers-and-acquisitions-in-derm-and-aesthetics-market-outlook/37631/We took a deeper look into the dermatology and aesthetics mergers and acquisitions (M&A) market in a conversation with two of our team members, Drew Thomas and Jordan Frickle, who are closely involved in this sector. The following discussion brings together their perspectives on current trends,The ESOP Model: An Alternative to PE for Dermatology Practices
https://practicaldermatology.com/issues/september-2025/the-esop-model-an-alternative-to-pe-for-dermatology-practices/37637/Not all practice models are as simple as private practice vs private equity. At Ada West Dermatology in Boise, Idaho, we’ve adopted a somewhat uncommon business model called an employee stock ownership plan (ESOP) and it’s worked very well for us.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuWe Are All From Somewhere
https://practicaldermatology.com/issues/july-2025/we-are-all-from-somewhere/36504/Everyone in dermatology has a story about where it all started and where choices were made to lead to the next steps. The common themes are baby steps, gratitude, and not closing the door behind them.Comorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.